Topoisomerase II-Alpha gene copy number alterations in ERBB2-Positive primary breast carcinomas: A fluorescence in situ hybridization study
A Colomer1, N Erill1, M Górriz1,2, M Verdú2, R Roman1, R Ibáñez1, C Cordon-Cardo1 and X Puig1,2.
1BIOPAT. Biopatologia Molecular, SL, Grup Assistència, Barcelona, Spain and 2 Histopat Laboratoris, Barcelona, Spain.
Background: Topoisomerase II-alpha gene (TOP2A) aberrations have been recently pointed as predictive markers of anthracycline-based adjuvant chemotherapy in breast cancer. While coamplification of ERBB2 and TOP2A seems to define a subgroup of high-risk patients likely to benefit from anthracycline treatment, the significance of a patient having TOP2A deletions in […]